Campath

Sickle Cell Anemia

Columbia UniversityPhase 2/3Active

BB

65/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 53/ 100
Competitive Position: 89/ 100

Competitive context

134 Active assets in the Sickle Cell Anemia cohort.

Asset / Sponsor	Phase	Rating
Glutamine Ain Shams University	Phase 4	BBB
Hydroxyurea St. Jude Children's Research Hospital	Phase 4	BB
Crizanlizumab Novartis Pharmaceuticals	Phase 4	BB
MAGNESIUM METALLICUM Medical College of Wisconsin	Phase 3	BB
FILGRASTIM St. Jude Children's Research Hospital	Phase 4	BB

View all 50 →

Same molecule, other indications

Campath is also rated in:

plasma cell myelomaDormant

B

Indicative ·

62 / 100

B-cell chronic lymphocytic leukemiaDormant

B

Indicative ·

59 / 100

myeloproliferative neoplasmDormant

B

Indicative ·

59 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.